Bluejay Diagnostics Inc (NASDAQ: BJDX) is a pre-revenue medical diagnostics company developing rapid, near-patient diagnostic tests for critical care settings, with a focus on sepsis detection. The company has no approved products and generates no product revenue as of the 10-K filed March 6, 2026, for fiscal year ended December 31, 2025. Its sole platform, Symphony, consists of an analyzer and single-use protein detection cartridges that run on whole blood samples. Symphony has not received FDA regulatory clearance and cannot be marketed in the United States. Bluejay transferred cartridge manufacturing from original developer Toray Industries to contract manufacturer Sanyoseiko Co., Ltd., which holds FDA certification, and is working with Sanyoseiko to resolve technical issues ahead of regulatory submission. The company has identified material weaknesses in internal controls and discloses a going-concern condition, requiring at least $20 million in additional capital by end of fiscal year 2027. Since its IPO in November 2021, the market price of its common stock has declined more than 99.9%, per the FY2025 10-K filing.

Revenue model

Bluejay generates no product revenue. The company is pre-commercialization and funds operations through equity offerings and securities purchase agreements. No transactional, subscription, or royalty revenue model is operational as of the FY2025 10-K.

Products and services

Symphony platform: a combination of a reusable analyzer and single-use protein detection cartridges using whole blood. Target biomarker includes IL-6 for sepsis detection. No regulatory clearance has been obtained in any country as of the FY2025 10-K filing.

Customers and end markets

Target end market is critical care settings, specifically sepsis diagnosis. No commercial customers exist as of the FY2025 10-K. Intended customers would be hospitals and near-patient clinical care facilities upon commercialization.

Value-chain role

Bluejay is a medical device developer occupying the research, development, and regulatory submission stages of the diagnostics value chain. Cartridge manufacturing is contracted to Sanyoseiko Co., Ltd. Core technology was originally developed with Toray Industries. Clinical studies SYMON-I and SYMON-II are cited as part of the FDA clearance pathway.

Geographic exposure

Development and regulatory activities are focused on the United States, requiring FDA clearance before any commercial launch. No international regulatory filings are described as active in the FY2025 10-K.

Source: SEC 10-K, filed 2026-03-06

Industry: Surgical & Medical Instruments & Apparatus Peers: Abbott Laboratories Vivos Inc Aethlon Medical Inc BIOLASE, INC Femasys Inc Guided Therapeutics Inc PetVivo Holdings Inc Tenon Medical Inc